Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Then theres tirzepatide (Mounjaro, Zepbound), a newer medication that not only targets GLP-1 but also GIP receptors, and studies show it may deliver even greater weight loss results and metabolic benefits
Alan Mathis, PharmD Candidate 2013, University of Florida College of Pharmacy The pathophysiology of type-2 diabetes is characterized by insulin resistance and beta-cell dysfunction
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
GIP receptor agonism Retatrutide activates glucose-dependent insulinotropic polypeptide (GIP) hormone receptors to enhance insulin secretion and glucose reuptake in cells and slow down gastric emptying
What to Expect with Retatrutide Retatrutide is administered as a once-weekly subcutaneous injection
